In this study, we reported that mirodenafil, a potent PDE5 inhibitor, ameliorates dermal fibrosis in a BLM-induced SSc mouse model by inhibiting the TGF-β signaling pathway, thereby suppressing the expression of collagen and profibrotic genes. This evidence concerns the gene PDE5A and systemic sclerosis.